Clinical and Prognostic Significance of Coagulation Assays in Gastric Cancer

Overview

Journal J Gastrointest Cancer

Publisher Springer

Specialties Gastroenterology
Oncology

Date 2013 Mar 29

PMID 23536321

Citations 9

Authors

Faruk Tas

Rumeysa Ciftci

Leyla Kilic

Murat Serilmez

Senem Karabulut

Derya Duranyildiz

Affiliations

Soon will be listed here.

Abstract

Purpose: Activation of coagulation and fibrinolysis is frequently found among cancer patients. Such tumors are considered to be associated with a higher risk of invasion, metastases, and eventually, worse outcome. The aim of this study is to explore the clinical and prognostic value of blood coagulation tests in gastric cancer (GC) patients.

Materials And Methods: A total of 44 consecutive patients with a pathologically confirmed diagnosis of GC were enrolled into the study. Pretreatment blood coagulation tests including prothrombin time (PT), activated partial thromboplastin time (APTT), international normalized ratio (INR), D-dimer (DD), fibrinogen (F) levels, and platelet (PLT) counts were evaluated. Control group comprised 50 age- and sex-matched individuals without history of malignancy and coagulation disorder.

Results: Median age at diagnosis was 55 years, range 19-80 years; most had men (n = 32, 73 %) and metastatic disease (n = 31, 70 %). The level of blood coagulation tests showed a statistically significant difference between the patient and the control groups (P < 0.001 for all, but p = 0.07 for PT). DD levels were significantly associated with elevated PLT and LDH levels (p = 0.009 and p = 0.01, respectively). Patients with metastatic disease had higher levels of F (p = 0.001) and INR (p = 0.027) levels. Elevated DD levels tended to be a poor prognostic factor on outcome (p = 0.06).

Conclusion: Change in almost all coagulation tests are found in GC patients and only DD level seems to be of prognostic value.

Citing Articles

Relationship Between Coagulation and Prognosis of Gastric Cancer: A Systematic Review and Meta-Analysis.

Zhu L, Liu S, Wang D, Yu M, Cai H Curr Ther Res Clin Exp. 2024; 101:100741.

PMID: 39628767 PMC: 11612816. DOI: 10.1016/j.curtheres.2024.100741.

Extracellular vesicles, hyperadhesive von willebrand factor, and outcomes of gastric cancer: a clinical observational study.

Cai W, Wang M, Wang C, Zhao C, Zhang X, Zhou Q Med Oncol. 2023; 40(5):140.

PMID: 37031314 DOI: 10.1007/s12032-023-01950-w.

D-dimer, a predictor of bad outcome in gastric cancer patients undergoing radical resection.

Zhang X, Wang X, Li W, Sun T, Dang C, Diao D Sci Rep. 2022; 12(1):16432.

PMID: 36180481 PMC: 9525585. DOI: 10.1038/s41598-022-16582-9.

Construction and validation of a novel coagulation-related 7-gene prognostic signature for gastric cancer.

Wang B, Zou D, Wang N, Wang H, Zhang T, Gao L Front Genet. 2022; 13:957655.

PMID: 36105100 PMC: 9465170. DOI: 10.3389/fgene.2022.957655.

Combination of preoperative fibrinogen and D-dimer as a prognostic indicator in pancreatic ductal adenocarcinoma patients undergoing R0 resection.

Zhang L, Ren H, Du Y, Zheng X, Zhang Z, Wang C World J Gastrointest Surg. 2021; 13(3):279-302.

PMID: 33796216 PMC: 7993003. DOI: 10.4240/wjgs.v13.i3.279.

References

Nierodzik M, Klepfish A, Karpatkin S . Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo. Thromb Haemost. 1995; 74(1):282-90. View

Fidan E, Kavgaci H, Orem A, Yilmaz M, Yildiz B, Fidan S . Thrombin activatable fibrinolysis inhibitor and thrombin-antithrombin-III-complex levels in patients with gastric cancer. Tumour Biol. 2012; 33(5):1519-25. DOI: 10.1007/s13277-012-0403-6. View

Kwon H, Oh S, Lee S, Kim S, Han J, Koh R . Plasma levels of prothrombin fragment F1+2, D-dimer and prothrombin time correlate with clinical stage and lymph node metastasis in operable gastric cancer patients. Jpn J Clin Oncol. 2008; 38(1):2-7. DOI: 10.1093/jjco/hym157. View

Siegel R, Naishadham D, Jemal A . Cancer statistics, 2012. CA Cancer J Clin. 2012; 62(1):10-29. DOI: 10.3322/caac.20138. View

PROKOPOWICZ J, Gabryelewicz A, WOLOSOWICZ N, Szalaj W, Puchalski Z . Peripheral and gastric fibrinolysis in patients with gastric carcinoma. Z Exp Chir. 1975; 8(5):309-12. View

Taguchi O, Gabazza E, Yasui H, Kobayashi T, Yoshida M, Kobayashi H . Prognostic significance of plasma D-dimer levels in patients with lung cancer. Thorax. 1997; 52(6):563-5. PMC: 1758583. DOI: 10.1136/thx.52.6.563. View

Di Micco P, Romano M, Niglio A, Nozzolillo P, Federico A, Petronella P . Alteration of haemostasis in non-metastatic gastric cancer. Dig Liver Dis. 2002; 33(7):546-50. DOI: 10.1016/s1590-8658(01)80105-5. View

Langer F, Holstein K, Eifrig B, Bokemeyer C . [Haemostatic aspects in clinical oncology]. Hamostaseologie. 2009; 28(5):472-80. View

Falanga A . Thrombophilia in cancer. Semin Thromb Hemost. 2005; 31(1):104-10. DOI: 10.1055/s-2005-863812. View

10.

Karpeh M, Leon L, Klimstra D, Brennan M . Lymph node staging in gastric cancer: is location more important than Number? An analysis of 1,038 patients. Ann Surg. 2000; 232(3):362-71. PMC: 1421150. DOI: 10.1097/00000658-200009000-00008. View

11.

Wada H, Mori Y, Okabayashi K, Gabazza E, Kushiya F, Watanabe M . High plasma fibrinogen level is associated with poor clinical outcome in DIC patients. Am J Hematol. 2003; 72(1):1-7. DOI: 10.1002/ajh.10249. View

12.

Lyman G, Khorana A . Cancer, clots and consensus: new understanding of an old problem. J Clin Oncol. 2009; 27(29):4821-6. PMC: 2764390. DOI: 10.1200/JCO.2009.22.3032. View

13.

Falanga A, Marchetti M, Vignoli A, Balducci D . Clotting mechanisms and cancer: implications in thrombus formation and tumor progression. Clin Adv Hematol Oncol. 2005; 1(11):673-8. View

14.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

15.

Palumbo J, Degen J . Fibrinogen and tumor cell metastasis. Haemostasis. 2002; 31 Suppl 1:11-5. View

16.

Khorana A . Risk assessment and prophylaxis for VTE in cancer patients. J Natl Compr Canc Netw. 2011; 9(7):789-97. DOI: 10.6004/jnccn.2011.0064. View

17.

Molnar S, Guglielmone H, Lavarda M, Rizzi M, Jarchum G . Procoagulant factors in patients with cancer. Hematology. 2007; 12(6):555-9. DOI: 10.1080/10245330701521416. View

18.

Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden P, Haglund U . Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997; 8(2):163-8. DOI: 10.1023/a:1008243606668. View

19.

Blackwell K, Haroon Z, Broadwater G, Berry D, Harris L, Iglehart J . Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. J Clin Oncol. 2000; 18(3):600-8. DOI: 10.1200/JCO.2000.18.3.600. View

20.

Kessler C . The link between cancer and venous thromboembolism: a review. Am J Clin Oncol. 2009; 32(4 Suppl):S3-7. DOI: 10.1097/COC.0b013e3181b01b17. View